Vergoeding 2020-2024 voor ATC-subgroep L04AC : Interleukineremmers
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| L04AC03 Anakinra | 4.012.922 | 4.023.770 | 4.328.602 | 4.696.105 | 4.475.269 |
| L04AC05 Ustekinumab | 72.573.609 | 88.797.715 | 105.001.133 | 135.883.007 | 129.600.896 |
| L04AC07 Tocilizumab | 28.445.914 | 37.700.815 | 30.819.465 | 36.000.988 | 28.470.917 |
| L04AC08 Canakinumab | 22.698.685 | 26.598.065 | 28.812.921 | 31.779.802 | 30.603.184 |
| L04AC10 Secukinumab | 24.456.853 | 29.600.525 | 31.269.439 | 34.262.398 | 36.051.206 |
| L04AC11 Siltuximab | 42.935 | 71.986 | 98.112 | 153.006 | 316.958 |
| L04AC12 Brodalumab | 949.513 | 2.849.732 | 2.480.600 | 2.315.367 | 2.104.772 |
| L04AC13 Ixekizumab | 9.248.031 | 10.318.522 | 12.109.323 | 15.467.509 | 16.856.596 |
| L04AC14 Sarilumab | 2.555.961 | 5.109.864 | 3.664.202 | 3.263.378 | 3.485.929 |
| L04AC16 Guselkumab | 7.967.544 | 10.252.580 | 12.821.411 | 16.128.402 | 17.693.717 |
| L04AC17 Tildrakizumab | 657.342 | 1.886.673 | 1.680.063 | 1.285.782 | 1.264.789 |
| L04AC18 Risankizumab | 2.065.251 | 4.741.838 | 7.252.786 | 9.679.034 | 14.352.777 |
| L04AC19 Satralizumab | . | . | . | 13.771 | 91.805 |
| L04AC21 Bimekizumab | . | 63.239 | 948.160 | 1.917.418 | 2.291.545 |
| L04AC22 Spesolimab | . | . | . | 71.940 | 35.071 |
| L04AC24 Mirikizumab | . | . | . | . | 19.458 |
| Totaal | 175.674.561 | 222.015.325 | 241.286.218 | 292.917.905 | 287.714.887 |